Nothing Special   »   [go: up one dir, main page]

Greenwald et al., 2013 - Google Patents

Paediatric rheumatology

Greenwald et al., 2013

View PDF
Document ID
12369543699427792430
Author
Greenwald A
Zakerzadeh A
Laxer R
Schneider R
Cameron B
Feldman B
Spiegel L
Tse S
Silverman E
Publication year
Publication venue
Clinical and Experimental Rheumatology

External Links

Snippet

Paediatric rheumatology Later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis (JIA): a unique patie Page 1 Clinical and Experimental Rheumatology 2013; 31: 645-652. Paediatric rheumatology Later-onset rheumatoid factor negative polyarticular …
Continue reading at www.clinexprheumatol.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
Arnett et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
FlatØ et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years.
Gore et al. Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis
Guillaume et al. Long‐term outcome and prognosis in oligoarticular‐onset juvenile idiopathic arthritis
Christiansen et al. Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event
Cantini et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study
Fu et al. Neutrophil-like low-density granulocytes are elevated in patients with moderate to severe persistent asthma
Wu et al. Juvenile dermatomyositis: latest advances
Barragán-Martínez et al. Gender differences in Latin-American patients with rheumatoid arthritis
Greenwald et al. Paediatric rheumatology
Papadopoulos et al. Early rheumatoid arthritis patients: relationship of age
Gilli et al. Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosis
Gmuca et al. Juvenile spondyloarthritis
Chambers et al. Birth outcomes in women who have taken hydroxycholoroquine during pregnancy: a prospective cohort study
Ganna The relationship between hemoglobin level and disease activity in patients with rheumatoid arthritis
Haidri Fibromyalgia complicating disease management in rheumatoid arthritis
Arguedas et al. A prospective population based study on outcome of juvenile chronic arthritis in Costa Rica.
Shenoi Juvenile Idiopathic Arthritis–Changing Times, Changing Terms, Changing Treatments
Massardo et al. Clinical expression of rheumatoid arthritis in Chilean patients
Martinelli et al. Pregnancy outcome after a first episode of cerebral vein thrombosis
Armon Outcomes for Juvenile idiopathic arthritis
Maher et al. Management of contraception in adolescent females with hormone-related venous thromboembolism
Malaviya Classification of spondyloarthritis: a journey well worth
Rinaldi et al. Long term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radiographic response
Moll Nonarteriosclerotic disorders of the arterial system